Inmolecule Nanotech (XPAR:MLINA) Operating Margin %: -11.00% (As of Dec. 2024)


XPAR:MLINA Inmolecule Nanotech SA XPAR:MLINA
6 GF Score
Price €4.08
! 2 Warning Signs
View Full Analysis

What is Inmolecule Nanotech Operating Margin %?

Inmolecule Nanotech XPAR:MLINA 6 Operating Margin % is -11.00% as of Dec. 2024. GuruFocus rates XPAR:MLINA with a GF Score™ of 6/100. The stock has 2 warning signs investors should review. Among 942 Biotechnology companies, Inmolecule Nanotech ranks better than 66.14% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Inmolecule Nanotech's Operating Income for the six months ended in Dec. 2024 was €-0.22 Mil. Inmolecule Nanotech's Revenue for the six months ended in Dec. 2024 was €1.98 Mil. Therefore, Inmolecule Nanotech's Operating Margin % for the quarter that ended in Dec. 2024 was -11.00%.

The historical rank and industry rank for Inmolecule Nanotech's Operating Margin % or its related term are showing as below:

XPAR:MLINA' s Operating Margin % Range Over the Past 10 Years
Min: -107.4   Med: -59.2   Max: -11
Current: -11.01


XPAR:MLINA's Operating Margin % is ranked better than
66.14% of 942 companies
in the Biotechnology industry
Industry Median: -86.83 vs XPAR:MLINA: -11.01

Inmolecule Nanotech's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Inmolecule Nanotech's Operating Income for the six months ended in Dec. 2024 was €-0.22 Mil.


Inmolecule Nanotech  (XPAR:MLINA) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Inmolecule Nanotech Operating Margin % Related Terms


Inmolecule Nanotech Operating Margin % Historical Data

* Premium members only.

The historical data trend for Inmolecule Nanotech's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inmolecule Nanotech Operating Margin % Chart

Inmolecule Nanotech Annual Data
Trend Dec23 Dec24
Operating Margin %
-107.40 -11.00

Inmolecule Nanotech Semi-Annual Data
Dec23 Dec24
Operating Margin % -107.40 -11.00

XPAR:MLINA vs VRTX, REGN, ALNY: Operating Margin % Comparison

For the Biotechnology subindustry, Inmolecule Nanotech's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inmolecule Nanotech Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inmolecule Nanotech's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Inmolecule Nanotech's Operating Margin % falls into.


XPAR:MLINA
6GF Score
Inmolecule Nanotech SA XPAR:MLINA
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Inmolecule Nanotech Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Inmolecule Nanotech's Operating Margin % for the fiscal year that ended in Dec. 2024 is calculated as

Operating Margin %=Operating Income (A: Dec. 2024 ) / Revenue (A: Dec. 2024 )
=-0.218 / 1.981
=-11.00 %

Inmolecule Nanotech's Operating Margin % for the quarter that ended in Dec. 2024 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2024 ) / Revenue (Q: Dec. 2024 )
=-0.218 / 1.981
=-11.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of -11.00% mean?
Inmolecule Nanotech (XPAR:MLINA) has a Operating Margin % of -11.00% as of Dec. 2024. Operating margin is the ratio of total operating income to net sales. View historical data on Inmolecule Nanotech and its competitors. According to the industry distribution chart, Inmolecule Nanotech ranks #319 out of 942 companies in the Biotechnology industry, placing it in the top 33.9%.
Is Inmolecule Nanotech's Operating Margin % too high?
Inmolecule Nanotech's current Operating Margin % is -11.00%. Based on the distribution chart, Inmolecule Nanotech ranks #319 out of 942 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Inmolecule Nanotech has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Inmolecule Nanotech's Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Inmolecule Nanotech ranks #319 out of 942 companies for Operating Margin %. This puts Inmolecule Nanotech in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Inmolecule Nanotech and its competitors. Inmolecule Nanotech's current Operating Margin % is -11.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inmolecule Nanotech stock overvalued right now?
Inmolecule Nanotech (XPAR:MLINA) has a current Operating Margin % of -11.00%. The current Operating Margin % is -11.00%. Inmolecule Nanotech's overall GF Score™ is 6/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Inmolecule Nanotech (XPAR:MLINA), the current Operating Margin % is -11.00% as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Inmolecule Nanotech Business Description

Address Paseo de la Castellana 91, 4th Floor, Madrid, ESP, 28046
Inmolecule Nanotech SA is a research and development company. The company provides health care, home care and personal care products.
6GF Score

Get the complete analysis for XPAR:MLINA

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.08
Price